{
    "clinical_study": {
        "@rank": "151286", 
        "arm_group": {
            "arm_group_label": "Imatinib and nilotinib combination", 
            "arm_group_type": "Experimental", 
            "description": "All patients will receive treatment as follows: imatinib 100 mg tablets, 200 mg daily for 6 months; and nilotinib 150 mg capsule, 300 mg daily for 6 months."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if low-dose imatinib and nilotinib combination,\n      will improve treatment results in CML patients with failure, suboptimal response or\n      intolerance to imatinib therapy.\n\n      The hypothesis is that with low-dose imatinib and nilotinib combination, major molecular\n      response will be achieved in patients not previously obtained with imatinib monotherapy."
        }, 
        "brief_title": "Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Leukemia, Myeloid, Chronic, BCR-ABL Positive", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  CML patients with failure or suboptimal response to imatinib therapy according to\n             criteria established by the European Leukemia Net (ELN)\n\n          -  Patients with grade II or higher adverse events.\n\n          -  CML patients not suitable for stem cell transplantation.\n\n        Exclusion Criteria:\n\n          -  Patients in blast crisis.\n\n          -  Pregnant women\n\n          -  Patients without a contraception method."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01819389", 
            "org_study_id": "HE12-019"
        }, 
        "intervention": {
            "arm_group_label": "Imatinib and nilotinib combination", 
            "intervention_name": "Imatinib and Nilotinib", 
            "intervention_type": "Drug", 
            "other_name": [
                "Gleevec", 
                "Tasigna"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Imatinib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chronic myeloid leukemia", 
            "suboptimal response", 
            "imatinib", 
            "nilotinib"
        ], 
        "lastchanged_date": "January 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Monterrey", 
                    "country": "Mexico", 
                    "state": "Nuevo Leon", 
                    "zip": "64460"
                }, 
                "name": "Servicio de Hematologia, Hospital Universitario \"Jos\u00e9 E. Gonzalez\""
            }
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "1", 
        "official_title": "Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance.", 
        "other_outcome": {
            "description": "Every month adherence will be assessed  with a questionnaire", 
            "measure": "Adherence", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Mexico: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Major molecular response will be evaluated with quantitative Real time polymerase chain reaction assay (RT-PCR)for BCR/ABL at 6 months.", 
            "measure": "Major molecular response", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "reference": [
            {
                "PMID": "20507881", 
                "citation": "Sch\u00f6ffski P, Reichardt P, Blay JY, Dumez H, Morgan JA, Ray-Coquard I, Hollaender N, Jappe A, Demetri GD. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol. 2010 Oct;21(10):1990-8. doi: 10.1093/annonc/mdq076. Epub 2010 May 27."
            }, 
            {
                "PMID": "22986736", 
                "citation": "G\u00f3mez-Almaguer D, Tar\u00edn-Arzaga L, Cant\u00fa-Rodr\u00edguez O, Ceballos-L\u00f3pez A. More about imatinib and nilotinib combination therapy in chronic myeloid leukemia. Acta Haematol. 2013;129(1):18-9. doi: 10.1159/000342455. Epub 2012 Sep 12."
            }, 
            {
                "PMID": "22286512", 
                "citation": "Zhu GR, Ji O, Ji JM, Zhang YC, Wu Y, Yu H, Jiang PJ, Shen Q. Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML. Acta Haematol. 2012;127(3):152-5. doi: 10.1159/000333107. Epub 2012 Jan 27."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01819389"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Universitario Dr. Jose E. Gonzalez", 
            "investigator_full_name": "David Gomez Almaguer", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Patients will be evaluated every four weeks to identify possible adverse effects of drugs administered.", 
            "measure": "Drugs adverese effects", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "Hospital Universitario Dr. Jose E. Gonzalez", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Hospital Universitario Dr. Jose E. Gonzalez", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}